Update shared on04 Sep 2025
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29.
What's in the News
- Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.
- Cencora entered into a distribution services agreement with Citius Oncology to support the commercial launch and distribution of LYMPHIR, an FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Valuation Changes
Summary of Valuation Changes for Cencora
- The Consensus Analyst Price Target remained effectively unchanged, at $333.29.
- The Net Profit Margin for Cencora remained effectively unchanged, at 0.85%.
- The Consensus Revenue Growth forecasts for Cencora remained effectively unchanged, at 6.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.